<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00889200</url>
  </required_header>
  <id_info>
    <org_study_id>0608-002</org_study_id>
    <nct_id>NCT00889200</nct_id>
  </id_info>
  <brief_title>Eszopiclone Treatment &amp; Cortisol Responsivity</brief_title>
  <official_title>Eszopiclone Treatment &amp; Cortisol Response to HPA Axis Tests</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Butler Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Butler Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to use a sensitive neuroendocrine probe, the
      Dexamethasone/Corticotropin-Releasing Hormone (DEX/CRH) test, in a sample of healthy adults
      with insomnia. The primary aim was to assess cortisol reactivity before and after long-term
      (6 weeks) administration of eszopiclone. It was hypothesized that treatment with eszopiclone
      would result in a significant reduction in plasma cortisol response to the DEX/CRH test
      following treatment of insomnia with standard dose of eszopiclone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      see above
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cortisol Response to the Dex/CRH Test Post-treatment (6 Weeks Oral Drug)</measure>
    <time_frame>post drug (6 weeks oral eszopiclone)</time_frame>
    <description>Cortisol reponse to the DEX/CRH test post-treatment is the same as measured and calculated at baseline =delta(CORT).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>Open-label Eszopiclone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard dosing of drug for 6 weeks for insomnia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eszopiclone</intervention_name>
    <description>6 weeks standard oral therapy</description>
    <arm_group_label>Open-label Eszopiclone</arm_group_label>
    <other_name>Lunesta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mild to Moderate Insomnia

        Exclusion Criteria:

          -  Any acute or chronic medical condition involving function of HPA axis (e.g., Cushing's
             or Addison's Disease, adrenal or pituitary gland disorders)

          -  Currently taking, or unable to be free of, antidepressant, neuroleptic, anxiolytic, or
             thymoleptic drugs for at least 2 weeks preceding the DEX/CRH test (free of fluoxetine
             for at least 6 weeks)

          -  Current use of psychotropic medication or medication (prescribed or over the counter)
             thought to affect HPA axis function or glucocorticoid synthesis/release (e.g.,
             prednisone, anabolic steroids, DHEA, ketoconazole, metyrapone)

          -  History of a significant adverse reaction to eszopiclone

          -  Meets DSM-IV criteria for any Axis I psychiatric disorder, including substance abuse
             presently, or substance dependence within the past 6 months

          -  Pregnancy, lactation, or unable/unwilling to use reliable methods of contraception
             during the study procedures

          -  Limited mental competency and the inability to give informed, voluntary, written
             consent to participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda Carpenter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Butler Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Butler Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2009</study_first_submitted>
  <study_first_submitted_qc>April 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2009</study_first_posted>
  <results_first_submitted>August 21, 2013</results_first_submitted>
  <results_first_submitted_qc>November 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 4, 2014</results_first_posted>
  <last_update_submitted>August 8, 2017</last_update_submitted>
  <last_update_submitted_qc>August 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Eszopiclone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from the community via flyers and through Internet and newspaper advertisements for “healthy adults experiencing problems with sleep.” Voluntary written informed consent was obtained for the study, which was approved by the Butler Hospital Institutional Review Board.</recruitment_details>
      <pre_assignment_details>Excluded subjects met criteria for current major depressive disorder (MDD) or other major Axis I psychiatric or substance use disorders. Subjects reporting &lt; 6 hours of sleep/night and with score &gt; 10 on Insomnia Severity Index (ISI) qualified. General good health required on physical and neurological examinations and on laboratory studies.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Open-label Eszopiclone</title>
          <description>Standard daily dosing of 3 mg drug nightly for 6 weeks for insomnia
eszopiclone : 6 weeks standard oral therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Open-label Eszopiclone</title>
          <description>Standard dosing of drug for 6 weeks for insomnia
eszopiclone : 6 weeks standard oral therapy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Depressive Symptoms</title>
          <description>Inventory for Depressive Symptomology-Self Report version (IDS-SR), total score calculated without 4 items pertaining to sleep. Range of scores on this version of the IDSSR are 0 (best outcome; no symptoms) to 69 (worst outcome; severe symptoms).</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.83" spread="8.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>plasma cortisol response to standardized dexamethasone/Corticotropin Releasing Hormone (DEX/CRH)</title>
          <description>Cortisol assays were performed on plasma samples from 2:59 PM (baseline), 3:30 PM, 3:45 PM, 4:00 PM, 4:15 PM, and 5:00 PM. Radioimmunoassay (RIA) used to measure cortisol in duplicate at each time point; intra-assay and inter-assay coefficients of variation observed for quality assessment samples (5 and 20 nmol/L) were &lt;5% and 10%, respectively. Cortisol &quot;response&quot;was summarized by absolute change from pre-CRH infusion (time point 0) to peak level after CRH infusion.</description>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="146.23" spread="161.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insomnia Severity Index</title>
          <description>Self report measure of Insomnia. Subjects had to have a total score &gt;10 to enroll. The range of the scales is from 0 (no insomnia symptoms) to 28 (severe insomnia symptoms).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.23" spread="2.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cortisol Response to the Dex/CRH Test Post-treatment (6 Weeks Oral Drug)</title>
        <description>Cortisol reponse to the DEX/CRH test post-treatment is the same as measured and calculated at baseline =delta(CORT).</description>
        <time_frame>post drug (6 weeks oral eszopiclone)</time_frame>
        <population>All subjects completed all study procedures</population>
        <group_list>
          <group group_id="O1">
            <title>Open-label Eszopiclone</title>
            <description>After Standard dosing of drug for 6 weeks for insomnia, Dex/CRH test was repeated to measure cortisol reactivity with the same neuroendocrine test</description>
          </group>
        </group_list>
        <measure>
          <title>Cortisol Response to the Dex/CRH Test Post-treatment (6 Weeks Oral Drug)</title>
          <description>Cortisol reponse to the DEX/CRH test post-treatment is the same as measured and calculated at baseline =delta(CORT).</description>
          <population>All subjects completed all study procedures</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>paired t-test cortisol reactivity</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>paired t-test cortisol reactivity</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.98" spread="129.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Over 6 weeks on drug; verbal report by subject at clinic assessments every 2 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Open-label Eszopiclone</title>
          <description>Standard dosing of drug for 6 weeks for insomnia
eszopiclone : 6 weeks standard oral therapy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Linda Carpenter, MD</name_or_title>
      <organization>Butler Hospital</organization>
      <phone>401 455 6349</phone>
      <email>Linda_Carpenter_MD@Brown.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

